Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Opdivo, Yervoy combo meets primary endpoint in phase 3 malignant pleural mesothelioma trial
BMS’ Opdivo, Yervoy combo meets primary endpoint in CheckMate -743 trial. (Credit: Rept0n1x/Wikipedia.org)
BMS’ Opdivo, Yervoy combo meets primary endpoint in CheckMate -743 trial. (Credit: Rept0n1x/Wikipedia.org)